MX2021004682A - Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer. - Google Patents

Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Info

Publication number
MX2021004682A
MX2021004682A MX2021004682A MX2021004682A MX2021004682A MX 2021004682 A MX2021004682 A MX 2021004682A MX 2021004682 A MX2021004682 A MX 2021004682A MX 2021004682 A MX2021004682 A MX 2021004682A MX 2021004682 A MX2021004682 A MX 2021004682A
Authority
MX
Mexico
Prior art keywords
cells
natural killer
composition
treating cancer
killer cells
Prior art date
Application number
MX2021004682A
Other languages
English (en)
Inventor
Sang Woo Park
Yong Man Kim
Jae Seob Jung
Yong-Hee Rhee
Original Assignee
Nkmax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR20190093499A/ko
Priority claimed from KR1020190001983A external-priority patent/KR20190093500A/ko
Application filed by Nkmax Co Ltd filed Critical Nkmax Co Ltd
Publication of MX2021004682A publication Critical patent/MX2021004682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un método para producir células asesinas naturales (NK). El método comprende aislar células mononucleares de sangre periférica (PBMCs) de una muestra de sangre; aislar al menos una de las células CD56+ y/o células CD3-/CD56+ de las PBMCs; y cocultivar la al menos una de las células CD56+ y/o células CD3-/CD56+ con una combinación de células alimentadoras en presencia de una citocina. También se describe una composición para tratar el cáncer. La composición comprende las células asesinas naturales CD56+ producidas por el método de la presente invención y una citocina.
MX2021004682A 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer. MX2021004682A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180012942 2018-02-01
KR20180012938 2018-02-01
KR1020190001981A KR20190093499A (ko) 2018-02-01 2019-01-07 자연살해세포의 생산방법
KR1020190001983A KR20190093500A (ko) 2018-02-01 2019-01-07 Cd56+ 자연살해세포를 포함하는 항암용 조성물

Publications (1)

Publication Number Publication Date
MX2021004682A true MX2021004682A (es) 2021-06-04

Family

ID=68465207

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008039A MX2020008039A (es) 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
MX2021004682A MX2021004682A (es) 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020008039A MX2020008039A (es) 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.

Country Status (14)

Country Link
US (3) US10590385B2 (es)
EP (1) EP3746095A4 (es)
JP (3) JP7268039B2 (es)
CN (2) CN111757745B (es)
AU (2) AU2019215034C1 (es)
BR (1) BR112020015512A2 (es)
CA (1) CA3089853A1 (es)
CL (1) CL2020002011A1 (es)
IL (1) IL276365B2 (es)
MX (2) MX2020008039A (es)
MY (1) MY197176A (es)
NZ (1) NZ766453A (es)
PH (1) PH12020551151A1 (es)
SG (1) SG11202007221QA (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118907A1 (en) 2016-12-21 2018-06-28 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN112626029B (zh) * 2020-12-22 2022-12-20 深圳市赛欧细胞技术有限公司 一种转基因修饰的Daudi细胞及其制备方法、应用
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2024036226A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells
CN117122612A (zh) * 2023-07-07 2023-11-28 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
CN116904397B (zh) * 2023-09-04 2023-12-26 山东德升细胞治疗工程技术有限公司 Nk细胞的细胞外囊泡的制备及应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320906C (en) 1986-06-04 1993-08-03 Daniel R. Twardzik Interleukin-2 induced antineoplastic peptide
EP0460101A4 (en) 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
GR1001034B (el) 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2002097070A1 (en) 2001-05-30 2002-12-05 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
ATE414176T1 (de) 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
AU2003275421A1 (en) 2002-10-03 2004-04-23 Andrea Bottaro Three-dimensional peripheral lymphoid organ cell cultures
JP4033390B2 (ja) 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
EP1755685A4 (en) 2004-05-28 2008-11-12 Mayo Foundation METHOD FOR AUTOLOGIC STRAIN CELL TREATMENT
AU2005302291B2 (en) 2004-11-02 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
AU2005309502B2 (en) 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
EP2399594B1 (en) 2005-03-17 2019-08-14 UCL Business PLC Tumour cell-activated Natural Killer cells
ES2368152T3 (es) 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
PL1941027T3 (pl) 2005-09-28 2015-01-30 Ipd Therapeutics B V Metody i środki do proliferacji komórek macierzystych oraz wytwarzania i ekspansji komórek progenitorowych, a także produkcji komórek efektorowych jako leków klinicznych
WO2007103901A2 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
EP2139498B1 (en) 2007-03-22 2015-03-18 Dendreon Corporation Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity
US9193953B2 (en) 2007-03-27 2015-11-24 Ipd-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells
KR100902340B1 (ko) 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
NO2227271T3 (es) 2007-12-07 2018-06-23
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
US8372642B2 (en) 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
WO2010110734A1 (en) 2009-03-26 2010-09-30 Avaris Ab Expansion of nk cells
TW201127959A (en) 2010-02-12 2011-08-16 Ivy Life Sciences Co Ltd Method of producing immune killer cell
EP2539442A1 (en) 2010-02-24 2013-01-02 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
KR20190108599A (ko) 2010-07-13 2019-09-24 안트로제네시스 코포레이션 천연 킬러 세포의 생성 방법
KR101145391B1 (ko) 2010-08-16 2012-05-15 고려대학교 산학협력단 말초혈액으로부터 자연 살해세포의 증식 방법
WO2012128622A1 (en) 2011-03-18 2012-09-27 Ipd-Therapeutics B.V. Generation of nk cells and nk-cell progenitors
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
NO2794859T3 (es) 2011-12-22 2018-02-17
CA2864283C (en) 2012-02-08 2020-11-03 Jan Spanholtz Ex vivo nk cell differentiation from cd34+ hematopoietic cells
EP2841563B1 (en) 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
US9938498B2 (en) * 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
HUE061931T2 (hu) 2012-06-28 2023-09-28 Univ Of Central Florida Módszerek és készítmények természetes ölõsejtek számára
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (ja) 2012-08-02 2016-02-09 阿部　博幸 単球またはｎｋ細胞を入手する方法
CN102988415B (zh) 2012-08-15 2014-11-19 中航（宁夏）生物有限责任公司 人异基因有核细胞工业化制备自然杀伤性细胞(nk)及注射液
AU2013349706B2 (en) 2012-11-21 2019-08-22 Assistance Publique - Hopitaux De Paris Methods for determining the risk of acute graft versus host disease
JP5997296B2 (ja) 2013-01-15 2016-09-28 阿部　博幸 免疫細胞含有組成物の製造方法及び癌治療用組成物
CN115137753A (zh) * 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
EP2986312B1 (en) 2013-04-19 2021-12-15 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
WO2015125113A1 (en) 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
WO2015132415A1 (en) * 2014-03-07 2015-09-11 Emercell Sas Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
CN106459914B (zh) * 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
JP7413639B2 (ja) 2014-06-11 2024-01-16 ポリバイオセプト ゲーエムベーハー 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
JP2016008198A (ja) * 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
JP2016077185A (ja) 2014-10-14 2016-05-16 学校法人 聖マリアンナ医科大学 γδＴ細胞の製造方法および医薬
KR20170100653A (ko) 2014-12-31 2017-09-04 안트로제네시스 코포레이션 천연 킬러 세포를 사용하여 혈액학적 장애, 고형 종양, 또는 감염 질환을 치료하는 방법
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
CN107267454A (zh) 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
WO2017188790A1 (ko) * 2016-04-29 2017-11-02 고려대학교 산학협력단 저산소 조건을 이용한 면역세포의 증식 배양 방법
CA3023239A1 (en) * 2016-05-07 2017-11-16 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
WO2018022646A1 (en) 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
KR101948534B1 (ko) 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 세포밀도 조절을 이용한 자연살해세포의 대량증식방법
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
AU2018309166B2 (en) 2017-08-03 2022-12-08 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CA3091671A1 (en) 2018-02-21 2019-08-29 Board Of Regents,The University Of Texas System Universal antigen presenting cells and uses thereof
WO2019168222A1 (ko) 2018-02-28 2019-09-06 주식회사 제넨셀 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법
WO2019175802A1 (en) 2018-03-13 2019-09-19 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
MX2020011697A (es) 2018-05-03 2020-12-10 Univ Texas Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario.
CA3102055A1 (en) 2018-05-30 2019-12-05 Glycostem Therapeutics B.V. Car nk cells
WO2020006139A1 (en) 2018-06-27 2020-01-02 The George Washington University Targeting stat sumoylation to enhance immune responses
WO2020095058A1 (en) 2018-11-08 2020-05-14 GammaDelta Therapeutics Limited Methods for isolating and expanding cells
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
CN111205361B (zh) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
EP3656851A1 (en) 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
WO2020112563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CA3121210A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
EP3908596A1 (en) 2019-01-07 2021-11-17 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
WO2020172328A1 (en) 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
CU20190021A7 (es) 2019-03-15 2020-10-20 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
US20220325245A1 (en) 2019-03-29 2022-10-13 Board Of Regents, The University Of Texas System Methods for production of car-nk cells and use thereof

Also Published As

Publication number Publication date
JP7339309B2 (ja) 2023-09-05
MY197176A (en) 2023-05-30
CN111757745A (zh) 2020-10-09
US20200172869A1 (en) 2020-06-04
CN115710576A (zh) 2023-02-24
EP3746095A1 (en) 2020-12-09
JP2021506333A (ja) 2021-02-22
MX2020008039A (es) 2021-09-20
US20190345449A1 (en) 2019-11-14
JP2022000060A (ja) 2022-01-04
EP3746095A4 (en) 2021-04-21
AU2019215034A1 (en) 2020-08-27
BR112020015512A2 (pt) 2021-01-26
JP2023153361A (ja) 2023-10-17
NZ766453A (en) 2022-02-25
CA3089853A1 (en) 2019-08-08
CN111757745B (zh) 2022-11-04
JP7268039B2 (ja) 2023-05-02
AU2019215034C1 (en) 2022-01-06
US10590385B2 (en) 2020-03-17
RU2020128764A (ru) 2022-03-01
CL2020002011A1 (es) 2021-02-12
AU2021266198A1 (en) 2021-12-02
AU2019215034B2 (en) 2021-08-19
IL276365B1 (en) 2023-06-01
PH12020551151A1 (en) 2021-09-01
RU2020128764A3 (es) 2022-03-01
IL276365B2 (en) 2023-10-01
US11066644B2 (en) 2021-07-20
US20210032597A1 (en) 2021-02-04
IL276365A (en) 2020-09-30
SG11202007221QA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
Laroni et al. IL-27 imparts immunoregulatory function to human NK cell subsets
EA201890996A1 (ru) Способ получения t-клеток для т-клеточной терапии
MX2020009359A (es) Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas.
Konjević et al. Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
DK1604016T3 (da) In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
WO2019178259A3 (en) Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
PH12021550035A1 (en) Combination therapy
RU2012148391A (ru) СПОСОБЫ ИДЕНТИФИКАЦИИ, ВЫДЕЛЕНИЯ, ИСТОЩЕНИЯ И ОБОГАЩЕНИЯ ПОПУЛЯЦИЙ Tr1 КЛЕТОК, ПОПУЛЯЦИИ Tr1 КЛЕТОК, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СПОСОБ МОНИТОРИНГА ЭФФЕКТА ТЕРАПИИ
Stabile et al. Reconstitution of multifunctional CD56lowCD16low natural killer cell subset in children with acute leukemia given α/β T cell-depleted HLA-haploidentical haematopoietic stem cell transplantation
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MY190805A (en) Antibody for treating autoimmune diseases
Helena et al. Reconstitution of multifunctional CD56lowCD16low natural killer cell subset in children with acute leukemia given α/β T cell-depleted HLA-haploidentical haematopoietic stem cell transplantation
MX2020008044A (es) Células asesinas naturales resistentes al factor de crecimiento transformante beta.
EA201992875A1 (ru) T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения